Tesamorelin for visceral fat — what the clinical trials actually show

Tesamorelin is interesting because it's one of the few peptides with actual FDA approval (for HIV-associated lipodystrophy). Here's what the clinical data shows for visceral fat reduction: - Clinical trials demonstrated 15-18% reduction in visceral adipose tissue over 6 months - Preferentially targets visceral fat (the deep, metabolically harmful belly fat) while having minimal effect on subcutaneous fat - Also showed improvements in liver fat, triglycerides, and liver enzymes - IGF-1 levels stay elevated for up to 28 days with repeated dosing Important caveats: Effects reverse after discontinuation if lifestyle changes aren't maintained. GH levels return to baseline. And the FDA approval is specifically for lipodystrophy, not general weight management — though the mechanism is the same. Of all the GH-releasing peptides, tesamorelin has the strongest clinical evidence base. That matters.